Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach

Breast Cancer

Volumn 18, Issue 1, 2011, Pages 64-67

  Takada, Masahiro ^a   Terunuma, Hiroshi ^b,c   Deng, Xuewen ^b   Dewan, Md Zahidunnabi ^d   Saji, Shigehira ^e   Kuroi, Katsumasa ^e   Yamamoto, Naoki ^f,g   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Biotherapy Institute of Japan   (Japan)

^c Tokyo Clinic Marunouchi Oazo mc   (Japan)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Breast cancer; Chemotherapy; Metastasis; Natural killer cell; Trastuzumab

Indexed keywords

CA 15-3 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; EPIRUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CELL THERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LUNG METASTASIS; MASTECTOMY; MONOTHERAPY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN METASTASIS; TRANSBRONCHIAL BIOPSY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; SALVAGE THERAPY; TAXOIDS;

EID: 79251602459     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-010-0198-5     Document Type: Article

References (22)

1. AD Thor S Liu S Edgerton D Moore 2nd KM Kasowitz CC Benz, et al. 2000 Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer J Clin Oncol 18 3230 3239 1:CAS:528:DC%2BD3cXntFOgu7k%3D 10986055
2. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
3. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 1:CAS:528:DC%2BD2MXhtFansr3L 10.1056/NEJMoa052306 16236737 (Pubitemid 41464705)
4. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
5. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446 1:CAS:528:DC%2BD3cXisVOru7Y%3D 10.1038/74704 10742152 (Pubitemid 30208162)
6. R Gennari S Menard F Fagnoni L Ponchio M Scelsi E Tagliabue, et al. 2004 Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin Cancer Res 10 5650 5655 1:CAS:528:DC%2BD2cXntlOqtb8%3D 10.1158/1078-0432.CCR-04-0225 15355889 (Pubitemid 39180938)
7. E Suzuki R Niwa S Saji M Muta M Hirose S Iida, et al. 2007 A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients Clin Cancer Res 13 1875 1882 1:CAS:528:DC%2BD2sXivV2gtb0%3D 10.1158/1078-0432.CCR-06-1335 17363544 (Pubitemid 46952958)
8. PJ Leibson 1997 Signal transduction during natural killer cell activation: inside the mind of a killer Immunity 6 655 661 1:CAS:528: DyaK2sXktFCqs7Y%3D 10.1016/S1074-7613(00)80441-0 9208838 (Pubitemid 27305728)
9. H Terunuma X Deng Z Dewan S Fujimoto N Yamamoto 2008 Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections Int Rev Immunol 27 93 110 1:CAS:528:DC%2BD1cXltFSgu7Y%3D 10.1080/08830180801911743 18437601 (Pubitemid 351589824)
10. MZ Dewan H Terunuma M Takada Y Tanaka H Abe T Sata, et al. 2007 Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo Breast Cancer Res Treat 104 267 275 1:CAS:528:DC%2BD2sXoslGhtL4%3D 10.1007/s10549-006-9416-4 17066321 (Pubitemid 47231275)
11. T Hayashi K Imai Y Morishita I Hayashi Y Kusunoki K Nakachi 2006 Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance Cancer Res 66 563 570 1:CAS:528:DC%2BD28XhsFWktA%3D%3D 10.1158/0008-5472.CAN-05-2776 16397273 (Pubitemid 43166065)
12. MZ Dewan M Takada H Terunuma X Deng S Ahmed N Yamamoto M Toi 2009 Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients Biomed Pharmacother 63 703 706 1:CAS:528:DC%2BD1MXhtlGit7bP 10.1016/j.biopha.2009.02.003 19269774
13. U Koehl J Sörensen R Esser S Zimmermann HP Grüttner T Tonn, et al. 2004 IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation Blood Cells Mol Dis 33 261 266 1:CAS:528:DC%2BD2cXpsV2rsbY%3D 10.1016/j.bcmd.2004.08.013 15528141 (Pubitemid 39446496)
14. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori, et al. 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281 1:CAS:528:DyaK1cXltlCgsrk%3D 10.1016/S0959-8049(98)00058-6 9849491 (Pubitemid 28342121)
15. M Toi H Bando S Horiguchi M Takada A Kataoka T Ueno, et al. 2004 Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Br J Cancer 90 2338 2343 1:CAS:528:DC%2BD2cXks1ahtrk%3D 15150550
16. N Sawada T Ishikawa Y Fukuse M Nishida T Yoshikubo H Ishitsuka 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013 1019 1:CAS:528:DyaK1cXisFeksr4%3D 9563897
17. M Toi MA Rahman H Bando LWC Chow 2005 Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment Lancet Oncol 6 128 166 10.1016/S1470-2045(05)01766-3 (Pubitemid 40309127)
18. M Kubo T Morisaki K Matsumoto A Tasaki N Yamanaka H Nakashima, et al. 2005 Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production Cancer Immunol Immunother 54 468 476 1:CAS:528:DC%2BD2MXhvFyrsb0%3D 10.1007/s00262-004-0617-6 15592829 (Pubitemid 40543686)
19. WE Carson 3rd CL Shapiro TR Crespin LM Thornton BL Andersen 2004 Cellular immunity in breast cancer patients completing taxane treatment Clin Cancer Res 10 3401 3409 1:CAS:528:DC%2BD2cXkt1GhsLk%3D 10.1158/1078-0432.CCR-1016-03 15161695 (Pubitemid 38685446)
20. H Terunuma A Wada X Deng Y Yasuma T Onishi A Toki, et al. 2007 Mild hyperthermia modulates the relative frequency of lymphocyte cell subpopulations: an increase in a cytolytic NK cell subset and a decrease in a regulatory T cell subset Therm Med 23 41 47 10.3191/thermalmedicine.23.41
21. Y Nagata KH Lan X Zhou M Tan FJ Esteva AA Sahin, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 1:CAS:528:DC%2BD2cXns1arsr8%3D 10.1016/j.ccr.2004.06.022 15324695 (Pubitemid 39485684)
22. K Berns HM Horlings BT Hennessy M Madiredjo EM Hijmans K Beelen, et al. 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 1:CAS:528:DC%2BD2sXht1ais7zL 10.1016/j.ccr.2007.08.030 17936563 (Pubitemid 47539306)